6-K
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of April 2006
Commission File Number – 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Name of Registrant)
7-1-27, Ameerpet
Hyderabad, Andhra Pradesh 500 016, India
+91-40-23731946
(Address of Principal Executive Offices)
Indicate by check mark whether registrant files or will file annual reports under cover of Form
20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant’s “home country”), or under the rules of the home country
exchange on which the registrant’s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant’s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule
12g3-2(b):
Not applicable.
| |
|
|
|
|
Press Release
|
|
|
|
[DR. REDDY’S LOGO] |
|
|
|
|
|
|
|
|
|
Dr. Reddy’s Laboratories Ltd. |
|
|
|
|
7-1-27 Ameerpet |
|
|
|
|
Hyderabad 500 016 India |
|
|
|
|
|
|
|
|
|
Tel: 91 40 373 1946 |
|
|
|
|
Fax: 91 40 373 1955 |
|
|
|
|
|
|
|
|
|
www.drreddys.com |
Dr Reddy’s launches ‘Z & D’ – Zinc therapy for effective management of diarrhea
April 3, 2006, Hyderabad, India: Dr Reddy’s has launched “Z&D”- a Zinc Sulphate formulation
indicated as Adjuvant therapy along with ORS in the management of Acute and persistent Diarrhea.
Available in 10 & 20 mg Dispersible orange flavoured Tablets as well as in 10mg/ml & 20mg/ml Dry
Syrup for pediatric use, this product is intended to supplement the ORS (Oral Rehydration Salt)
market.
Dr. Reddy’s is pioneer of low osmolarity ORS in India as per WHO /UNICEF guidelines. In diarrhea
management Dr Reddy’s has a complete basket of Brands Like Rebalanz, Redotil, Lactiflora and
Econorm. WHO/UNICEF and the Indian Academy of Pediatrics have jointly recommended that Zinc therapy
along with ORS is a very effective management tool for Diarrhea. WHO / UNICEF have also stressed on
the need to create awareness among clinicians, other health care providers and general public about
the use of ZINC along with ORS. Dr Reddy’s launch of this Zinc Formulation will complement its
existing product portfolio and will also support a social initiative under its program — “Drive
against Diarrhea”.
Z & D has been launched nationwide and will be available for prescription by mid April 2006. The
launch of the product will commence with a series of activities across the country in form of CMEs
(Continuing Medical Education), Patient Education Programs, Awareness Camps and Social Mobilization
Events like ORS Marathons.
With the Z & D meeting the WHO specifications, being economically priced and with leading
pediatricians of the country having endorsed the therapy based on sound clinical studies, talks are
on with UNICEF for their Global requirement.
Notes to the Editor:
| • |
|
Dr. Reddy’s had earlier taken up a social initiative named “Drive against Diarrhea”, in the year 2003-04. |
| • |
|
Under this initiative, many activities were planned and executed for awareness creation and promotion of low
osmolarity ORS. A nationwide implementation of ORS week, organizing awareness camps, conducting and supporting CMEs
and free distribution of ORS samples was done. |
| • |
|
Also under “Drive against Diarrhea” program eminent pediatricians and gastroenterologists were brought in common
forum for formulating a practical guidebook on “current concepts in the management of Diarrhea”. This book was
released by His Excellency; The President of India Dr. APJ Abdul Kalam and is well referred by many doctors and
health workers nationwide. |
| • |
|
Dr Reddy’s – Rebalanz is a low osmolarity ORS, Redotil is potent encephalinase inhibitor (anti hyper secretory
agent), Lactiflora is a bacterial probiotic and Econorm is the unique biotherapeutic agent (saccharomyces boulardii
– yeast probiotic). |
About Dr. Reddy’s
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical
company with proven research capabilities. The Company is vertically integrated with a presence
across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical
ingredients and biotechnology products and markets them globally, with focus on India, US, Europe
and Russia. The Company conducts research in the areas of diabetes, cardiovascular,
anti-infectives, inflammation and cancer.
3
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
Contact Information
Dr. Reddy’s:
Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-55511532
Media:
M Mythili at mythilim@drreddys.com or on +91-40-55511620
4
| |
|
|
|
|
Press Release
|
|
|
|
[DR. REDDY’S LOGO] |
|
|
|
|
|
|
|
|
|
Dr. Reddy’s Laboratories
Ltd.
7-1-27 Ameerpet
Hyderabad 500 016 India |
|
|
|
|
|
|
|
|
|
Tel: 91 40 373 1946
Fax: 91 40 373 1955 |
|
|
|
|
|
|
|
|
|
www.drreddys.com |
Dr. Reddy’s receives USFDA approval for fexofenadine hydrochloride
Hyderabad, India, April 13, 2006: Dr. Reddy’s Laboratories (NYSE:RDY) announced that the U. S. Food
and Drug Administration has granted final approval for the Company’s Abbreviated New Drug
Application (ANDA) for fexofenadine hydrochloride tablets 30 mg, 60 mg and 180 mg. The Company will
commence the commercial marketing of this product immediately.
In September 2002, Dr. Reddy’s filed the ANDA for fexofenadine hydrochloride tablets 30 mg, 60 mg
and 180 mg with a Para IV certification on all orange book patents. Dr. Reddy’s was granted summary
judgment with respect to 3 patents. Five patents remain in the litigation. The litigation is
pending at the United States District Court for the District of New Jersey. No date is currently
set for trial.
The 30-month period identified in section 505(j)(5)(B)(iii) of the Federal Food, Drug and Cosmetic
Act has expired. The 180-day generic drug exclusivity awarded to Barr Laboratories has also
expired.
Fexofenadine hydrochloride is the AB-rated generic equivalent of Sanofi-Aventis’ Allegra®. Allegra®
is indicated for the relief of symptoms associated with seasonal allergic rhinitis and for the
treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and
children 6 years of age and older. As per IMS December 2005, the product had annual US brand sales
of approximately $1.4 billion.
About Dr. Reddy’s
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical
company with proven research capabilities. The Company is vertically integrated with a presence
across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical
ingredients and biotechnology products and markets them globally, with focus on India, US, Europe
and Russia. The Company conducts research in the areas of diabetes, cardiovascular,
anti-infectives, inflammation and cancer.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
Contact Information
Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-55511532
Media:
M Mythili at mythilim@drreddys.com or on +91-40-55511620
5
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
|
|
|
|
| |
|
DR. REDDY’S LABORATORIES LIMITED |
|
|
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
| |
|
By: |
|
/s/ V. Viswanath |
| |
|
|
|
|
Date: May 11, 2006
|
|
|
|
Name:
|
|
V. Viswanath |
|
|
|
|
Title:
|
|
Company Secretary |
6